Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 10 for:    Oocyte Maturation Defect 2

Taurine Supplementation on Cognitive Function in Patients With Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03410173
Recruitment Status : Recruiting
First Posted : January 25, 2018
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Zhiming Zhu, Third Military Medical University

Brief Summary:

Diabetes has become important risk factors for threatening human life and health. Studies have shown that chronic hyperglycemia lead to microvascular brain injury. The more common types of dementia are Alzheimer's disease (AD). Cognitive dysfunction is a precursor to Alzheimer's disease. Mild cognitive impairment (MCI) is a cognitive impairment between normal aging and dementia, mainly manifested as memory impairment, especially episode memory defects, but also named obstacles, but the overall cognitive function is normal, daily life ability is normal. Studies have shown that middle-aged diabetic patients' cognitive ability will decline by about 19% in 20 years compared to people without diabetes.

Sulfur amino acid is the indispensable amino acid in mammals, and its metabolites include Taurine, Hydrogen sulfide (H2S) and sulfur dioxide (SO2). Taurine was first isolated more than 150 years ago from ox (Taurus) bile. Although the taurine can be synthesized in vivo by cysteine in the presence of cysteine dioxygenase, it is mainly acquired from dietary sources, such as eggs, meat, and seafood. H2S is a biologically relevant mediator and plays potential roles in several physiological processes and disease states in the body. H2S is synthesized from 2 sulfur-containing amino acids, l-cysteine andl-methionine, by the 3 enzymes,cystathionine-γ-lyase (CSE), cystathionine-β-synthetase(CBS), and3-mercaptopyruvate sulfurtransferase (3-MST). Previous studies have demonstrated that Taurine and H2S may play important roles in the development of themicroangiopathy and lower extremity arterial occlusive.


Condition or disease Intervention/treatment Phase
Taurine Cognitive Decline Diabetes Mellitus Drug: Taurine Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled Clinical Trial Comparing Effects of Taurine Supplementation on Cognitive Function in Patients With Diabetes
Actual Study Start Date : January 2017
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Taurine

Arm Intervention/treatment
Experimental: Taurine
2.4mg/d for 12 weeks
Drug: Taurine
Placebo Comparator: Placebo
2.4mg/d for 12 weeks
Drug: Placebo



Primary Outcome Measures :
  1. Changes of cognitive function assessed by cognitive function scale after 12 weeks. [ Time Frame: Baseline, 12weeks(End of Trial) ]

Secondary Outcome Measures :
  1. 24-hours mean blood pressure. [ Time Frame: Baseline, 12weeks(End of Trial) ]
  2. Fasting plasma glucose [ Time Frame: Baseline, 12weeks(End of Trial) ]
  3. HbA1c [ Time Frame: Baseline, 12weeks(End of Trial) ]
  4. Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) [ Time Frame: Baseline, 12weeks(End of Trial) ]
  5. Carotid intima-media thickness(IMT) [ Time Frame: Baseline, 12weeks(End of Trial) ]
  6. Body mass index(BMI) [ Time Frame: Baseline, 12weeks(End of Trial) ]
  7. Fasting serum insulin. [ Time Frame: Baseline, 12weeks(End of Trial) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes

Exclusion Criteria:

  • Type2 diabetes with acute diabetic complications.
  • Type1 diabetes.
  • History of depression, schizophrenia or dementia.
  • History of cardio-cerebral vascular events, such as congestive heart failure, myocardial infarction or stroke within 3 months.
  • History of parkinson's diseases, head injury,toxic encephacopathy,epilepsy.
  • Hypohepatia (AST or AST is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy.
  • Renal insufficiency (serum creatinine 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome.
  • Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction.
  • Fertile woman without contraceptives.
  • Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.
  • Allergic to or have contraindication to the intervention drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03410173


Contacts
Layout table for location contacts
Contact: Yan Zhencheng, MD 86-023-68757882 zhenchengyan@sina.com
Contact: Zhu Zhiming, MD 86-23-68767881 zhuzm@yahoo.com

Locations
Layout table for location information
China, Chongqing
The third hospital affiliated to the Third Military Medical University Recruiting
Chongqing, Chongqing, China, 400042
Contact: Yan Zhencheng, MD    86-023-68757882    zhenchengyan@sina.com   
Sponsors and Collaborators
Third Military Medical University

Layout table for additonal information
Responsible Party: Zhiming Zhu, MD,PhD,Director, Third Military Medical University
ClinicalTrials.gov Identifier: NCT03410173     History of Changes
Other Study ID Numbers: TSCFD
First Posted: January 25, 2018    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Cognitive Dysfunction
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cognition Disorders
Neurocognitive Disorders
Mental Disorders